ES2385251A1 - Adenovirus oncolíticos para el tratamiento del cáncer. - Google Patents

Adenovirus oncolíticos para el tratamiento del cáncer. Download PDF

Info

Publication number
ES2385251A1
ES2385251A1 ES200901201A ES200901201A ES2385251A1 ES 2385251 A1 ES2385251 A1 ES 2385251A1 ES 200901201 A ES200901201 A ES 200901201A ES 200901201 A ES200901201 A ES 200901201A ES 2385251 A1 ES2385251 A1 ES 2385251A1
Authority
ES
Spain
Prior art keywords
art
adenovirus
oncolytic
cancer
vol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200901201A
Other languages
English (en)
Other versions
ES2385251B1 (es
Inventor
Sònia Guedán Carrió
Manel María Cascalló Piqueras
Ramón Alemany Bonastre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut D Investigacio Biomedica De Bell
Original Assignee
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Institut Catala dOncologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2385251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL, Institut Catala dOncologia filed Critical Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Priority to ES200901201A priority Critical patent/ES2385251B1/es
Priority to CA2761183A priority patent/CA2761183C/en
Priority to BRPI1011445A priority patent/BRPI1011445B8/pt
Priority to PCT/ES2010/000196 priority patent/WO2010128182A1/es
Priority to PL10772050.0T priority patent/PL2428229T5/pl
Priority to JP2012509064A priority patent/JP2012525833A/ja
Priority to EP10772050.0A priority patent/EP2428229B2/en
Priority to MX2011011818A priority patent/MX2011011818A/es
Priority to CN201710271203.8A priority patent/CN107252438A/zh
Priority to CN201080028895XA priority patent/CN102548584A/zh
Priority to RU2011149458/10A priority patent/RU2536931C2/ru
Priority to KR1020117029097A priority patent/KR101878274B1/ko
Priority to US13/318,876 priority patent/US10316065B2/en
Priority to AU2010244348A priority patent/AU2010244348B2/en
Priority to HK12108533.3A priority patent/HK1167818B/en
Priority to ES10772050T priority patent/ES2600955T5/es
Priority to FIEP10772050.0T priority patent/FI2428229T4/fi
Publication of ES2385251A1 publication Critical patent/ES2385251A1/es
Publication of ES2385251B1 publication Critical patent/ES2385251B1/es
Application granted granted Critical
Priority to HK18104062.5A priority patent/HK1244679A1/zh
Priority to US16/405,285 priority patent/US12129280B2/en
Priority to US18/774,209 priority patent/US20250011373A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Adenovirus oncolíticos para el tratamiento del cáncer.La invención se refiere a un adenovirus oncolítico que comprende una secuencia que codifica una enzima hialuronidasa insertada en su genoma. Este adenovirus se distribuye más eficientemente por la masa tumoral y por consiguiente se aumenta el efecto oncolítico. Inyectando el adenovirus oncolítico de la invención endovenosamente se obtienen regresiones del volumen tumoral. Por lo tanto el adenovirus oncolítico de la presente invención es útil para el tratamiento del cáncer o de un estado pre-maligno del mismo.

Claims (2)

  1. REIVINDICACIONES
    1
    OFICINA ES ANOLA DE ATENTES Y MARCAS
    N.° solicitud:
    ES ANA
    Fecha de presentaci6n de la solicitud: 6. .
    3 Fecha de prioridad:
    INFORME SOBRE EL ESTADO DE LA TECNICA
    Int. Cl. : C12N151861 ( 6. ) A61K48100 ( 6. )
    DOCUMENTOS RELEVANTES
    Categoria
    ® Documentos citados Reivindicaciones afectadas
    Y Y Y Y Y GANESH S. et al.: "Relaxin� espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor�bearingmice', CANCER RES, ( 7), vol. 67, no. , 7, paginas 43 �44 7, todo el documento. KIM JO O�HANG et al .: "Relaxin e xpression f rom t umor�targeting ade noviruses and its intratumoral spread, apoptosis induction, and efficacy", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY RESS, GB, ( 6), vol 8, n° , pag. 48 � 4 3, todo el documento. GANESH S.: "Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models", ( 8), CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, n° , pag. 3 33� 3 4 , todo el documento. JIN CHENG et al.: "Human Matrix Metalloproteinase 8 Gene Delivery increases the Oncolytic Activityof a Replicating Adenovirus", ( 7), MOLECULAR THERA Y, vol. �, n° , pag. 8 � , todo el documento. TOOLE B et al.: "Hyaluronan; A constitutive regulator of chemoresistance and malignancyin cancer cells", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC UBLICATIONS, HILADEL HIA, A, US, ( 8), vol. 8, n° 4, pag. 44� � , todo el documento.
    Categoria de los documentos citados X: de particular relevancia Y: de particular relevancia combinado con otro/s de la misma categoria A: refleja el estado de la tecnica O: referido a divulgaci6n no escrita : publicado entre la fecha de prioridad yla de presentaci6n de la solicitud E: documento anterior, pero publicado despues de la fecha de presentaci6n de la solicitud
    El presente informe ha sido realizado � para todas las reivindicaciones � para las reivindicaciones n°:
    Fecha de realizaci6n del informe 3. 7. Examinador M. Hernandez Cuellar Pagina /4
    INFORME DEL ESTADO DE LA TECNICA
    N° de solicitud:
    Documentaci6n minima buscada (sistema de clasificaci6n seguido de los simbolos de clasificaci6n) C N, A6 K Bases de datos electr6nicas consultadas durante la busqueda (nombre de la base de datos y, si es posible, terminos de
    busqueda utilizados) E ODOC, W I, MEDLINE, EMBASE, BIOSIS, CA LUS
    Informe del Estado de la Tecnica agina /4
    OPINION ESCRITA
    N° de solicitud:
    Fecha de Realizaci6n de la Opini6n Escrita: 3. 7.
    Declaraci6n
    Novedad (Art. .1 LP 11/198 ) Reivindicaciones SI Reivindicaciones NO
    Actividad inventiva (Art. 8.1 LP11/198 ) Reivindicaciones SI Reivindicaciones NO
    Se considera que la solicitud cumple con el requisito de aplicaci6n industrial. Este requisito fue evaluado durante la fase de examen formal y tecnico de la solicitud (Articulo 3 . Ley / 86).
    Base de la Opini6n.-
    La presente opini6n se ha realizado sobre la base de la solicitud de patente tal y como se publica.
    Informe del Estado de la Tecnica agina 3/4
    OPINION ESCRITA
    N° de solicitud:
    1. Documentos considerados.-
    A continuaci6n se relacionan los documentos pertenecientes al estado de la tecnica tomados en consideraci6n para la realizaci6n de esta opini6n.
    Documento
    Numero Publicaci6n o Identificaci6n Fecha Publicaci6n
    D
    GANESH S. et al.: "Relaxin� espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor �bearing mice', CANCER RES, ( 7), vol. 67, n o. , 7, paginas 43 �44 7, todo el documento.
    D
    KIM JOO�HANG et al.: "Relaxin expression from tumor�targeting adenoviruses and i ts intratumoral sp read, apoptosis induction, and ef ficacy", JO URNAL O F THE NATIONAL CA NCER INSTITUTE, OXFORD UNIVERSITY RESS, GB, ( 6), vol 8, n° , pag. 48 � 4 3, todo el documento.
    D 3
    GANESH S.: "Intratumoral coadministration of hyaluronidase enzyme an d oncolytic adenoviruses enhances virus potency i n metastatic tumor m odels", ( 8), C LINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, n° , pag. 3 33� 3 4 , todo el documento.
    D 4
    JIN CHE NG et al .: "H uman Ma trix Metalloproteinase�8 Gene Delivery i ncreases the O ncolytic Activity of a R eplicating Adenovirus", ( 7), MO LECULAR T HERA Y, vol. �, n° , pag. 8 � , todo el documento.
    D �
    TOOLE B et al.: "Hyaluronan; A constitutive regulator of chemoresistance and malignancy in cancer cells", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC UBLICATIONS, HILADEL HIA, A, US, ( 8), vol. 8, n° 4, pag. 44�� , todo el documento.
  2. 2. Declaraci6n motivada segun los articulos 29. y 29.7 del Reglamento de ejecuci6n de la Ley 11/198 , de 20 de marzo, de Patentes sobre la novedad y la actividad inventiva; citas y explicaciones en apoyo de esta declaraci6n
    La presente invenci6n se refiere a adenovirus oncoliticos que tienen una secuencia que codifica una hialuronidasa insertada en su genoma, asi como a composiciones farmaceuticas que comprenden el citado adenovirus y su uso para la fabricaci6n de un medicamento para el tratamiento del cancer.
    .� NOVEDAD Ninguno de los documentos citados describe adenovirus oncoliticos que tienen una secuencia que codifica una hialuronidasa insertada e n s u ge noma. E n co nsecuencia l as reivindicaciones cumplen e l r equisito de nov edad establecido en el Art. 6. L / 86.
    .�ACTIVIDAD INVENTIVA Cualquiera de los documentos D y D se puede considerar representativo del estado de la tecnica mas cercano a la invenci6n. Ambos documentos describen un adenovirus oncolitico que comprende una secuencia que codifica relaxina insertada en su genoma. La diferencia entre la informaci6n aportada en ambos documentos y la reivindicaci6n es la elecci6n de la hialuronidasa como el gen expresado por el adenovirus oncolitico. El efecto de esta diferencia es el mismoque el mostrado en ambos documentos, es decir, la degradaci6n de la matriz extracelular de las celulas tumorales para facilitar la diseminaci6n del adenovirus y mejorar su eficacia. El problema subyacente de la reivindicaci6n se puede plantear como la provisi6n de un adenovirus oncolitico alternativo con el mismo prop6sito. La soluci6n que proporciona la reivindicaci6n es un adenovirus oncolitico que tienen una secuencia que codifica una hialuronidasa insertada en su genoma. El documento D � describe la capacidad de la hialuronidasa para degradar la matriz extracelular de las celulas tumorales y permitir una diseminaci6n eficiente de los adenovirus oncoliticos que mejora la actividad anti tumoral, tal y como se describe en D 3. En este sentido se considera que la capacidad de degradar la matriz extracelular asi como su posible uso para mejorar la diseminaci6n y eficacia de un adenovirus oncolitico era informaci6n accesible para un experto en la materia con anterioridad la presentaci6n de la solicitud de patente. A la vista de la mejora proporcionada por la expresi6n de una enzima que degrada la matriz extracelular por el adenovirus oncolitico en vez de la coadministraci6n de la hialuronidasa con el adenovirus oncolitico, el experto en la materia habria conseguido el objeto de la reivindicaci6n sin esfuerzo inventivo. Las reivindicaciones dependientes tambien carecen de actividad inventiva ya que corresponden a realizaciones que se consideran rutinarias en el estado de la tecnica. Finalmente, losadenovirus oncoliticos descritos en el estado de la tecnica se usan para el tratamiento del cancer. En este sentido, los usos terapeuticos de las reivindicaciones y tambien carecen de actividad inventiva. En consecuencia, las reivindicaciones no cumplen el requisito establecido en el Art. 8. L / 86.
    Informe del Estado de la Tecnica agina 4/4
ES200901201A 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer. Expired - Fee Related ES2385251B1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
ES200901201A ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.
RU2011149458/10A RU2536931C2 (ru) 2009-05-06 2010-05-05 Онколитический аденовирус для лечения рака, его применение и фармацевтическая композиция, содержащая его
US13/318,876 US10316065B2 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
PCT/ES2010/000196 WO2010128182A1 (es) 2009-05-06 2010-05-05 Adenovirus oncolíticos para el tratamiento del cáncer
PL10772050.0T PL2428229T5 (pl) 2009-05-06 2010-05-05 Onkolityczne adenowirusy do leczenia raka
JP2012509064A JP2012525833A (ja) 2009-05-06 2010-05-05 癌治療のための腫瘍溶解アデノウイルス
EP10772050.0A EP2428229B2 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
MX2011011818A MX2011011818A (es) 2009-05-06 2010-05-05 Adenovirus oncoliticos para el tratamiento del cancer.
CN201710271203.8A CN107252438A (zh) 2009-05-06 2010-05-05 用于治疗癌症的溶瘤腺病毒
CN201080028895XA CN102548584A (zh) 2009-05-06 2010-05-05 用于治疗癌症的溶瘤腺病毒
CA2761183A CA2761183C (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
KR1020117029097A KR101878274B1 (ko) 2009-05-06 2010-05-05 암 치료용 암 용해성 아데노바이러스
BRPI1011445A BRPI1011445B8 (pt) 2009-05-06 2010-05-05 Adenovírus oncolíticos para o tratamento de câncer
AU2010244348A AU2010244348B2 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
HK12108533.3A HK1167818B (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
ES10772050T ES2600955T5 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
FIEP10772050.0T FI2428229T4 (fi) 2009-05-06 2010-05-05 Onkolyyttisiä adenoviruksia syövän hoitoon
HK18104062.5A HK1244679A1 (zh) 2009-05-06 2018-03-23 用於治疗癌症的溶瘤腺病毒
US16/405,285 US12129280B2 (en) 2009-05-06 2019-05-07 Oncolytic adenoviruses for treating cancer
US18/774,209 US20250011373A1 (en) 2009-05-06 2024-07-16 Oncolytic adenoviruses for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200901201A ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.

Publications (2)

Publication Number Publication Date
ES2385251A1 true ES2385251A1 (es) 2012-07-20
ES2385251B1 ES2385251B1 (es) 2013-05-06

Family

ID=43050014

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200901201A Expired - Fee Related ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.
ES10772050T Active ES2600955T5 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10772050T Active ES2600955T5 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer

Country Status (15)

Country Link
US (3) US10316065B2 (es)
EP (1) EP2428229B2 (es)
JP (1) JP2012525833A (es)
KR (1) KR101878274B1 (es)
CN (2) CN102548584A (es)
AU (1) AU2010244348B2 (es)
BR (1) BRPI1011445B8 (es)
CA (1) CA2761183C (es)
ES (2) ES2385251B1 (es)
FI (1) FI2428229T4 (es)
HK (1) HK1244679A1 (es)
MX (1) MX2011011818A (es)
PL (1) PL2428229T5 (es)
RU (1) RU2536931C2 (es)
WO (1) WO2010128182A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CN103405480B (zh) * 2013-05-03 2015-11-25 浙江理工大学 10-羟基喜树碱-丁二酸与腺病毒结合物及制法和用途
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
ES2987442T3 (es) * 2015-05-04 2024-11-14 Theriva Biologics S L Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer
CN104946601A (zh) * 2015-05-28 2015-09-30 金宁一 重组溶瘤腺病毒及其应用
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2016403583B2 (en) * 2016-04-22 2020-05-28 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
KR102624967B1 (ko) * 2016-04-29 2024-01-16 이노비오 파마수티컬즈, 인크. 제제의 전달을 향상시키기 위한 콘드로이티나제 및/또는 히알루로니다제의 생체내 용도
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
US20190350992A1 (en) * 2016-11-17 2019-11-21 Vcn Biosciences Sl Use of viral vectors in the treatment of retinoblastoma
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
EP3703723A4 (en) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
CN111542601A (zh) 2017-11-08 2020-08-14 国立大学法人鹿儿岛大学 确保安全并且能够有效地治疗甚至转移性癌症的、具有提供装载的免疫诱导基因的最佳表达水平的表达控制系统的肿瘤溶解性病毒(肿瘤溶解性免疫治疗)
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
CN109913422A (zh) * 2017-12-13 2019-06-21 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
BR112020014727A2 (pt) * 2018-01-19 2020-12-08 Kolon Life Science, Inc. Vírus vaccinia recombinante e composição farmacêutica compreendendo o mesmo
CN111094324B (zh) * 2018-03-14 2023-10-10 武汉博威德生物技术有限公司 一种溶瘤病毒、合成dna序列及其应用
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
KR102650991B1 (ko) 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
AU2020325825B2 (en) 2019-08-05 2026-02-05 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
US12221638B2 (en) 2020-08-07 2025-02-11 Alteogen Inc. Method for producing recombinant hyaluronidase
CA3188492A1 (en) 2020-08-10 2022-02-17 Silviu Itescu Cellular compositions and methods of treatment
RU2753742C1 (ru) * 2020-10-16 2021-08-24 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Рекомбинантный штамм Ad6-hTERT-GMCSF, содержащий встройку промотора теломеразы человека hTERT, а также гена гранулоцитарно-макрофагального колониестимулирующего фактора человека, обладающий избирательной цитолитической активностью против теломераза-положительных опухолевых клеток и экспрессирующий активный человеческий гранулоцитарно-макрофагальный колониестимулирующий фактор
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
CN114703186B (zh) * 2022-03-31 2023-08-29 四川大学 肿瘤特异性启动子及其应用
CN117379389B (zh) * 2022-07-12 2026-03-06 四川大学 血小板-溶瘤病毒复合物、其制备方法及其应用
CN120693167A (zh) * 2022-09-19 2025-09-23 特里瓦生物制剂有限责任公司 溶瘤腺病毒与拓扑异构酶i抑制剂或其前药的组合疗法
EP4602078A2 (en) 2022-10-11 2025-08-20 Yale University Compositions and methods of using cell-penetrating antibodies
AU2024344897A1 (en) * 2023-09-20 2026-04-09 Theriva Biologics, S.L. Oncolytic adenovirus and topoisomerase i inhibitors for use in treating a cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
EP0872552A1 (en) 1997-04-15 1998-10-21 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
US5516631A (en) 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20040048821A1 (en) 1997-06-27 2004-03-11 Cold Spring Harbor Laboratory Enhancement of drug cytotoxicity in tumor cells containing mutant Rb gene
IL137681A0 (en) 1998-02-06 2001-10-31 Uab Research Foundation Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
IL142337A0 (en) 1998-10-15 2002-03-10 Canji Inc Selectively replicating viral vectors
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
JP2002530085A (ja) 1998-11-18 2002-09-17 カンジ，インコーポレイテッド 後期導入遺伝子の発現を有するウイルスベクター
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
ATE540686T1 (de) 1999-05-12 2012-01-15 Uab Research Foundation Adenovirus mit erhöhter infektiosität und konditionaler replikationsfähigkeit und deren verwendungen
CN1382218A (zh) 1999-11-15 2002-11-27 昂尼克斯药物公司 溶瘤腺病毒
US7078030B2 (en) 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
WO2002004511A2 (en) 2000-07-10 2002-01-17 Board Of Regents, The University Of Texas System CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
US7109029B2 (en) 2001-02-23 2006-09-19 Cell Genesys, Inc. Vector constructs
HUP0400882A3 (en) 2001-05-11 2011-01-28 Wellstat Biologics Corp Oncolytic virus therapy
EP1516055A4 (en) 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
WO2003072703A2 (en) 2002-02-05 2003-09-04 Cornell Research Foundation, Inc. Adenoviral vector with replication-dependent transgene expression
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
WO2003100031A2 (en) 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
US20080124360A1 (en) * 2003-01-24 2008-05-29 Seggern Daniel J Von Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
WO2005018332A1 (en) * 2003-08-13 2005-03-03 The General Hospital Corporation Modified microorganisms for anti-cancer therapy
WO2005030927A2 (en) * 2003-09-23 2005-04-07 Uab Research Foundation Methods and compositions for in vivo inflammation monitoring
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
WO2006096815A2 (en) 2005-03-09 2006-09-14 Board Of Regents, The University Of Texas System NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES
US20070172846A1 (en) * 2005-11-12 2007-07-26 Introgen Therapeutics, Inc. Methods for the Production and Purification of Adenoviral Vectors
US20090311664A1 (en) 2005-12-22 2009-12-17 Yuman Fong Method for Detection of Cancer Cells Using Virus
SI4269578T1 (sl) * 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
CA3089587A1 (en) * 2018-02-08 2019-08-15 Sangamo Therapeutics, Inc. Engineered target specific nucleases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GANESH S,: ¿Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenovíruses enhances virus potency in metastatic tumor models¿, (2008), CL1NICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, nº 12, pág. 3933-3941, todo el documento. *
GANESH S. ET AL: ¿Relaxin- espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice¿, CANCER RES, (2007), vol. 67, no. 9, 2007, pages 4399-4407, todo el documento. *
JIN CHENG ET AL: ¿Human Matrix Metalloproteinase-8 Gene Delivery increases the Oncolytic Activity of a Replicating Adenovirus¿, (2007), MOLECULAR THERAPY, vol.. 15, nº 11, pág. 1982-1990, todo el documento. *
KIM JOO- HANG ET AL; ¿Relaxin expression from tumor- targetíng adenoviruses and its intratumoral spread, apoptosís induction, and efficacy¿, JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, ( 2006), vol 98, nº 20, 1 pág. 1482-1493, todo el documento. *
TOOLE B P ET AL: ¿Hyaluronan; A constitutive regulator of chemoresistance and malignancy in cancer cells¿, SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHTA, PA, US, (2008), vol. 18, nº 4, pág. 244-250, todo el documento. *

Also Published As

Publication number Publication date
WO2010128182A1 (es) 2010-11-11
BRPI1011445A2 (pt) 2020-09-15
CA2761183C (en) 2019-03-26
CN102548584A (zh) 2012-07-04
EP2428229B2 (en) 2025-05-21
ES2600955T5 (en) 2025-10-02
EP2428229B1 (en) 2016-08-03
US10316065B2 (en) 2019-06-11
AU2010244348A1 (en) 2011-12-01
KR20120049185A (ko) 2012-05-16
JP2012525833A (ja) 2012-10-25
ES2385251B1 (es) 2013-05-06
US20250011373A1 (en) 2025-01-09
AU2010244348B2 (en) 2016-08-11
BRPI1011445B8 (pt) 2022-10-25
PL2428229T3 (pl) 2017-02-28
PL2428229T5 (pl) 2025-08-18
KR101878274B1 (ko) 2018-07-13
CA2761183A1 (en) 2010-11-11
US20190345204A1 (en) 2019-11-14
RU2011149458A (ru) 2013-06-27
FI2428229T4 (fi) 2025-07-29
HK1167818A1 (en) 2012-12-14
EP2428229A1 (en) 2012-03-14
ES2600955T3 (es) 2017-02-13
US12129280B2 (en) 2024-10-29
RU2536931C2 (ru) 2014-12-27
US20120148535A1 (en) 2012-06-14
BRPI1011445B1 (pt) 2022-10-04
HK1244679A1 (zh) 2018-08-17
CN107252438A (zh) 2017-10-17
MX2011011818A (es) 2012-06-19

Similar Documents

Publication Publication Date Title
ES2385251A1 (es) Adenovirus oncolíticos para el tratamiento del cáncer.
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
Sloane et al. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window
Date et al. Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles
Wang et al. Small mitochondria-targeting molecules as anti-cancer agents
Musicco et al. Mitochondria deregulations in cancer offer several potential targets of therapeutic interventions
BRPI0608297A2 (pt) composições de lipossomos
Linowiecka et al. Melatonin: a potential regulator of DNA methylation
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
BR112013019628A2 (pt) conjugados de polímero-carboidrato-lipídeo
AR084938A1 (es) Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
BRPI0819152B8 (pt) composição farmacêutica tópica
CO6640324A2 (es) Uso de metformina en combinación con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa
Workenhe et al. Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
Golla et al. Photodynamic therapy combined with Bcl-2/Bcl-xL inhibition increases the Noxa/Mcl-1 ratio independent of Usp9X and synergistically enhances apoptosis in glioblastoma
Yu et al. Insights into the pathogenesis and treatment of chemotherapy-induced neuropathy: A focus on oxidative stress and neuroinflammation
JOP20230173A1 (ar) أشطر إطالة العمر-النصفي وطرق استخدامها
BRPI0417616A (pt) carboxamidas opticamente ativas e seu uso para o combate de microorganismos indesejáveis
Mangoni et al. Secondary Metabolites and Peptides as Unique Natural Reservoirs of New Therapeutic Leads for Treatment of Cancer and Microbial Infections
Sánchez-Romero et al. Biobancos, laboratorios clínicos e investigación biomédica
HE Research Progress of siRNA Drugs
Ruiz Evaluación de accesibilidad en sitios web educativos
Anikeeva et al. Formal and non-formal education in enhancing the well-being and security of older adults
Cheng Prion diseases: a review.

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELL

Effective date: 20120220

FG2A Definitive protection

Ref document number: 2385251

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20130506

FD2A Announcement of lapse in spain

Effective date: 20210915